InflaRx (IFRX) Q4 2025 earnings review
GOHIBIC Commercial Failure Forces Strategic Reset to Izicopan
InflaRx is reversing its corporate strategy, officially abandoning its U.S. commercial efforts for GOHIBIC and writing off its remaining inventory. With full-year 2025 revenue at a negligible €29,331, management is aggressively cutting costs to survive. R&D spending and operating cash burn are decelerating significantly, extending the company's cash runway to mid-2027. The entire investment thesis now hinges on a single asset: izicopan, an oral C5aR inhibitor, which showed promising Phase 2a data in Hidradenitis Suppurativa (HS).
🐂 Bull Case
By cutting marketing spend and terminating the GOHIBIC U.S. commercialization, InflaRx reduced its operating cash burn by 27% YoY to €35.3M. This preserves the remaining €46.2M in cash to fund operations to mid-2027, bridging the gap to crucial Phase 2b izicopan data.
Phase 2a results in HS showed rapid and deepening reduction of abscesses and draining tunnels. If this biologic-like efficacy translates to Phase 2b, the drug addresses a market management believes exceeds $1 billion.
🐻 Bear Case
The GOHIBIC commercial rollout was a complete failure, generating just €29k in FY25 while forcing a €4.0M inventory write-down. The company has a history of expensive late-stage clinical and commercial missteps.
With the Phase 3 pyoderma gangrenosum (PG) trial terminated for futility and GOHIBIC shelved, InflaRx is now effectively a single-asset, early-stage clinical company. Any regulatory or clinical delay for izicopan could be fatal given the limited cash buffer.
⚖️ Verdict: 🔴
Bearish. While management's decision to stop the GOHIBIC cash bleed is necessary, the company is starting over. The timeline to commercialization has been pushed back years, and the €46.2M cash position leaves little room for error as they enter expensive Phase 2b trials.
Key Themes
GOHIBIC Write-Downs and Commercial Surrender
Management has completely reversed its commercial strategy for GOHIBIC. Due to a failure to gain market traction, the company recorded €4.0M in inventory write-downs in FY25—writing off product that will expire before it can be sold. FY25 revenue was an abysmal €29,331, compared to a cost of sales of €7.3M. The drug will now only be available 'on a reactive basis' in the U.S.
Izicopan Phase 2a Validates Biological Activity
Phase 2a data for izicopan in HS and Chronic Spontaneous Urticaria (CSU) provides the sole bright spot. In HS, the drug induced rapid, meaningful reductions in abscesses and nodules. Crucially, responses continued to deepen four weeks post-treatment, showing biologic-like disease modification. The FDA discussions for Phase 2b design are currently underway.
Vilobelimab PG Trial Fallout Requires a Partner
After the Phase 3 trial for vilobelimab in Pyoderma Gangrenosum (PG) was terminated for futility earlier this year, management claims post-hoc analyses show a 'positive trend'. However, they explicitly stated that any future development will only happen with a partner. This signals that InflaRx is unwilling to risk its own remaining capital on vilobelimab.
R&D Expense Profile is Decelerating
Research and development expenses dropped dramatically from €35.4M in 2024 to €25.7M in 2025. This €9.6M reduction is driven by lower third-party manufacturing and clinical trial costs, reflecting the shift away from expensive Phase 3/commercial preparations toward earlier-stage Phase 2 studies.
Other KPIs
Decelerating. Down from €52.8M at the end of 2024. The liquidity consists of €16.0M in cash and €30.2M in marketable securities. The company recognized a €5.7M non-cash gain from the fair value remeasurement of pre-funded warrants, which helped insulate the bottom-line net loss, but does not add to operational liquidity.
Decelerating. Down 34% YoY from €6.8M in 2024. This reflects the termination of third-party commercial contracts and aggressive personnel cuts as the company ends active GOHIBIC promotion.
Decelerating. Down from €5.3M in 2024. This primarily reflects lower reimbursements from the German Research Allowance Act. The company remains eligible for reimbursements through 2027, which provides a small but necessary non-dilutive funding stream.
Guidance
Stable to improving slightly vs prior phrasing ('into 2027'). The extension is entirely driven by the aggressive cuts to the GOHIBIC commercial infrastructure and the conclusion of the vilobelimab Phase 3 trial. However, executing a robust Phase 2b program for izicopan could easily accelerate cash burn again.
Key Questions
Phase 2b Cost Estimates
With €46.2M in available funds and a historical operating burn rate of €35M, how much of the projected Phase 2b izicopan trial in HS is fully funded by the current balance sheet?
GOHIBIC Lingering Liabilities
Now that GOHIBIC commercial efforts are effectively shuttered and inventory written off, are there any remaining severance or contract termination penalties that will hit the cash flow statement in H1 2026?
AAV Strategy Execution
You highlighted minimal CYP3A4/5 inhibition as a competitive advantage for izicopan in AAV. Given your tightened budget, how do you plan to finance proof-of-concept studies in this new indication without a partnership?